Avidity Partners Management LP Inozyme Pharma, Inc. Transaction History
Avidity Partners Management LP
- $445 Million
- Q1 2025
Shares
3 transactions
Others Institutions Holding INZY
# of Institutions
97Shares Held
46MCall Options Held
13.8KPut Options Held
1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$20.5 Million0.01% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$17.9 Million5.72% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17 Million0.29% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.87MShares$15.4 Million0.39% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.45MShares$13.7 Million0.19% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $160M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...